Guardian Pharmacy Services, Inc.
GRDN NYSE Retail-Drug Stores And Proprietary Stores Financials FY2024–FY2025
What Guardian Pharmacy Services, Inc. does
No business description yet.
- Legal name
- Guardian Pharmacy Services, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Accession · CIK
- 0001193125-26-102172
0001802255
Revenue and margins
Guardian Pharmacy Services, Inc. had $1.4B of revenue in fiscal 2025, up 17.9% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $86.8M in fiscal 2025, 6.0% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Guardian Pharmacy Services, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Guardian Pharmacy Services, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $4.7M | $65.6M |
| Debt incl. finance leases | $0.0M | $0.0M |
| Net debt / EBITDA | — | −0.7x |
| Debt / equity | 0.0x | 0.0x |
| Interest coverage | −19.2x | 109.3x |
| Current ratio | 1.1x | 1.4x |
| Quick ratio | 0.8x | 1.1x |
| Total assets | $321M | $413M |
| Total liabilities | $171M | $195M |
| Shareholders' equity | $150M | $218M |
| Net debt (− = net cash) | −$4.7M | −$65.6M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✓ |
| Cash from operations is positive | ✓ | ✓ |
| Return on assets rose | — | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | ✕ |
| Current ratio rose | — | ✓ |
| Share count didn't rise | — | — |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✕ |
| F-score | — / 3 | 6 / 8 |
| Accruals ratio | −52.4% | −13.9% |
| Altman Z'' | −0.06 | 3.85 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $1.2B | $1.4B |
| Gross profit | $244M | $293M |
| Operating income | −$62.9M | $72.7M |
| Interest expense | $3.3M | $0.7M |
| Pretax income | −$66.5M | $73.4M |
| Income tax | $4.6M | $24.5M |
| Net income | −$110M | $49.2M |
| Cash flow | ||
| Cash from operations | $58.0M | $100M |
| Capital expenditure | $14.7M | $13.4M |
| Free cash flow | $43.3M | $86.8M |
| Depreciation and amortization | $19.8M | $22.3M |
| Stock-based compensation | $131M | $13.9M |
| Balance sheet | ||
| Cash and short-term investments | $4.7M | $65.6M |
| Total debt | $0.0M | $0.0M |
| Current assets | $152M | $222M |
| Current liabilities | $144M | $161M |
| Inventory | $40.6M | $43.4M |
| Property and equipment, net | $49.9M | $55.5M |
| Goodwill | $69.3M | $79.7M |
| Intangible assets | $14.9M | $18.5M |
| Total assets | $321M | $413M |
| Total liabilities | $171M | $195M |
| Shareholders' equity | $150M | $218M |
| Margins | ||
| Gross margin | 19.9% | 20.2% |
| Operating margin | −5.1% | 5.0% |
| EBITDA margin | −3.5% | 6.6% |
| Net margin | −9.0% | 3.4% |
| FCF margin | 3.5% | 6.0% |
| Returns | ||
| Return on capital | −34.2% | 31.8% |
| Return on capital employed | −35.6% | 28.9% |
| Return on equity | −73.4% | 26.8% |
| Return on assets | −34.3% | 13.4% |
| Return on tangible equity | −167.3% | 41.1% |
| Growth | ||
| Revenue growth | — | 17.9% |
| FCF growth | — | 100.8% |
| Financial health | ||
| Net debt / EBITDA | — | −0.7x |
| Debt / equity | 0.0x | 0.0x |
| Interest coverage | −19.2x | 109.3x |
| Current ratio | 1.1x | 1.4x |
| Quick ratio | 0.8x | 1.1x |
| Capital allocation | ||
| Capex / revenue | 1.2% | 0.9% |
| Stock comp / revenue | 10.7% | 1.0% |
| Quality scores | ||
| Piotroski F-score | — | 6.0 |
| Altman Z'' | −0.1 | 3.9 |
| Accruals ratio | −52.4% | −13.9% |
Source: SEC EDGAR XBRL filings (CIK 0001802255). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.